Compare Las Vegas Sands Corp. (LVS) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs McKesson Corporation — how do they compare? Las Vegas Sands Corp. trades at $45.69 (market cap $29.44B), while McKesson Corporation trades at $888.37 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 3.6× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| LVS | MCK | |
|---|---|---|
Market Cap | $29.44B | $105.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $995.69 |
52-Week Low | $44.78 | $659.01 |
Enterprise Value | $41.33B | $111.67B |
Dividend Yield | 2.64% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.68, up 0.48% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue grew to $13.02B in 2025, with net income of $1.63B and a 12.59% margin. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains strong profitability metrics, including a 48.52% gross margin and 134.29% ROE. Positive news includes ESG recognitions and community initiatives, supporting a stable operational outlook.
The stock presents a buy opportunity with a consensus price target of $60.75, implying 33% upside, backed by 59% analyst buy ratings. Risks include high debt levels, with a debt-to-asset ratio of 73.15% in 2025, and sensitivity to macroeconomic factors affecting the gaming and tourism sectors. Institutional sentiment remains positive, but investors should monitor debt management and regional economic conditions for sustained growth.
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
